News

The need to see real-time study performance is vital, as teams focus on meeting timelines and ensuring resources are appropriately allocated, writes EVP of WCG, Jonathan Zung.

Peter O’Donnell writes of the support of ‘disruptive’ change in European health systems from European health professionals and policymakers from a recent gathering.

David Freeman, General Manager, Information Ventures, for Quest Diagnostics, discusses how his company can be an effective partner for pharma and biotech firms.

As advanced therapy technology and manufacturing evolve, there are three key operational challenges to address unique to these products.

Despite mounting frustrations in drug R&D for Alzheimer's disease, emerging biophar­ma firms are still pursuing AD therapies with new science, and differ­ent preclinical and clinical trial models.

Regulatory enforcement actions, policy updates, and new guidelines show that ensuring the reliability of clinical data is an ongoing priority.

Click the title above to open the Applied Clinical Trials October 2019 issue in an interactive PDF format.

The transformation in patient perceptions will only happen when the five million Americans who’ve already participated in clinical trials can directly share their experiences with the next five million people considering participating.

A look at the findings from Avoca Group’s 2018 industry research survey on clinical outsourcing.

A strongly-worded plan for reining-in profit-driven drug firms receives immediate backlash as arguments over drug pricing and patient access continue to rage around Europe and the US.

A recent survey shows that 40% of pediatric trials conducted between 2008 and 2011 were never finished or published. One of the main challenges is the need to collect multiple sequential blood samples. Which, mircosampling, could be the answer to.

CEO of Synteract, Steve Powell, discusses the advantages that mid-sized CROs-like his own-offer emerging drug developers to navigate continually changing processes.

A strongly-worded plan for reining-in profit-driven drug firms receives immediate backlash as arguments over drug pricing and patient access continue to rage around Europe and the US.

COO and CMO of BrainStorm, Ralph Kern, discusses how his company is overcoming challenges and advancing science in neurodegenerative disease.